Immunotherapy-Chemo cocktail targets tough colon cancer before surgery
NCT ID NCT06124378
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial is testing whether adding the immunotherapy drug tislelizumab to standard chemotherapy (oxaliplatin and capecitabine) before surgery can help shrink tumors in people with a specific type of locally advanced colon cancer called microsatellite stable (MSS). About 60 participants will receive the combination for 2 to 4 cycles, then have surgery. The main goal is to see how many patients have no cancer cells left in their surgical specimen.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tislelizumab (Tevimbra) combined with oxaliplatin (Eloxatin) and capecitabine (Xeloda)
- What this could lead to
- If successful, this combination could become a new option to shrink tumors before surgery in patients with a hard-to-treat type of colon cancer.
- What could go wrong
- This is a small, early-phase study with no control group, so results may not apply broadly. The added immunotherapy could cause immune-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLONIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, 530021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Four-Drug combo erase Triple-Negative breast cancer before surgery?
- Can an immune booster after lung cancer surgery keep the disease at bay?
- Could a COVID-19 shot boost cancer immunotherapy? a massive study digs into the timing.
- Can a triple threat of drug, immunotherapy, and radiation wipe out High-Risk urinary tract cancer before surgery?
- Could a Triple-Drug attack before surgery eliminate more breast cancer in older women?
- Scientists probe hidden clues to immunotherapy success in endometrial cancer